Background: Fibrosis in liver with hepatitis C virus (HCV) recurrence post-liver transplantation
INTRODUCTION
Currently hepatitis C virus (HCV)-associated cirrhosis is the commonest indication for liver transplantation (LT) worldwide. [1] [2] [3] It is now established that recurrent HCV infection is associated with a 23% increased mortality rate and a 30% increased allograft failure rate compared to transplant performed for non-HCV related indications. 4 HCV re-infection of the allograft is inevitable, leading to allograft hepatitis in 50-80% at 2 years. 5-10 HCV-related fibrosis is accelerated in the post-LT immunocompromised patient compared to the pre-LT patient, 11 with cirrhosis observed in 21% of patients at 5 years. 6 It has been reported that the median duration from transplantation to HCV-related allograft cirrhosis is approximately 9-12 years with a 42% risk for hepatic decompensation at 1 year after the development of cirrhosis.
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The pathogenesis of liver injury in chronic HCV infection prior to LT has been extensively investigated. Following HCV infection and resultant chronic intrahepatic inflammation, hepatocytes are continuously damaged and undergo replicative arrest, which activates an intrahepatic stem celllike compartment of hepatic progenitor cells (HPCs). [13] [14] [15] Dependent on the injury, HPCs either proliferate as ductular structures, 16 or as strings of parenchymal cells, which can appear as single cells in two-dimensional sections. 17 They migrate from periportal to pericentral areas to mediate liver regeneration. 18, 19 As the proliferation of HPCs generally is of a ductular phenotype, in human liver they are referred to as the "ductular reaction" (DR). 13, 20 However, HPCs are not confined to the DR and non-ductular strings of HPCs, which sometimes appear as single cells, are frequently observed in adjacent areas. 17 HPCs and the DR are spatially and temporarily associated with fibrosis-driving hepatic stellate cells (HSCs) and a close relationship between the DR, HPCs, inflammation and fibrosis has been repeatedly reported in liver with HCV infection. [13] [14] [15] 21 Importantly, it has been established in the pre-LT setting that HPC numbers and the amplitude of the DR directly correlate with the severity of fibrosis. [13] [14] [15] 21 Interactions between the DR, HPCs and HSCs are mediated via a number of autocrine and paracrine pathways, which are poorly characterized but thought to drive progressive fibrosis. 16, 17, [22] [23] [24] [25] [26] [27] [28] [29] A recent study outlined a role for HPC proliferation in HCV-associated fibrosis progression post-LT. 30 This study reported an increased expression of keratin (K)-19, an HPC and biliary epithelial marker, in individuals with rapid liver fibrosis. 31 K19 is a commonly used marker for the DR but not unique as K7 and pan-keratin (Kpan) have similarly been reported as markers delineating the same intrahepatic injury response. 32, 33 Although a number of immunohistochemistry markers of the DR are available, the role of the DR and HPC proliferation in post-LT liver injury characterized by rapid fibrosis does require further study. In particular, it is not known whether the complex relationships between the DR, HPC proliferation, fibrosis and inflammation seen in non-transplant HCV-associated liver injury are recapitulated in the post-LT setting. This is an important question to answer in order to better understand the pathogenesis of recurrent HCV and to develop predictive markers of aggressive recurrence.
To examine co-regulation of DR, HPC and liver injury responses in recurrent HCV post-LT, we studied two distinct LT cohorts. The initial large characterization cohort was used to assess the relationships between the DR, replicative arrest, steatosis and fibrosis in livers with HCV recurrence post-LT in comparison to donor livers, which served as normal controls. The independent second cohort was used to confirm the DR-associated findings of the initial characterization cohort and to extend them by also comparing the DR, inflammation and fibrosis in the post-versus pre-LT HCV-associated liver injury.
MATERIALS AND METHODS

Patient Cohorts
Retrospective studies were conducted in Australia at the Australian National Liver Transplantation 
Immunohistochemistry
Immunohistochemistry was performed on formalin-fixed, paraffin-embedded liver biopsies using the following primary antibodies: K7 (ductular epithelium and HPC) 
Quantification and image analysis
Scanning of tissue sections and image analyses were performed using the Dako Automated Cellular
Imaging System® III (Sydney cohort), and the Aperio ScanScope whole slide scanning system and ImageScope software (Loma Linda cohort), using algorithm-based positive pixel count per area.
Further, both the Sydney and Loma Linda cohort were quantitated by experienced liver pathologists and hepatologists for the extent of the DR as well as quantitation of the HPC response in at least three random high power fields per section. As previously described, HPCs were quantitated by counting small, immunoreactive cells in the periportal area and expressing them as the number per portal tract. 34 Hepatocyte proliferation and replicative arrest were assessed by counting Ki-67-positive and p21-positive hepatocyte nuclei, respectively, in ten random lobular fields at 400X magnification, and expressing this as a percentage of total hepatocyte nuclei to correct for cellular enlargement caused by steatosis. The replicative arrest ratio was determined by calculating the ratio (p21-positive nuclei) ÷ (Ki-67-positive nuclei). 
Histopathological analysis
Sections were analyzed by experienced liver pathologists who were blinded to the clinical data and laboratory parameters. Scheuer's scoring system was used in the initial cohort and this consists of necroinflammatory activity assessment in the portal and lobular areas (0-4) and fibrosis staging (0-4). 35 Steatosis was graded as 0 (<5% hepatocytes affected), 1 (5-29% of hepatocytes affected), 2 (30-70% of hepatocytes affected), or 3 (>70% of hepatocytes affected). 13 The Loma Linda cohort used Ishak's scoring system of fibrosis.
Immunofluorescence and confocal microscopy
Immunofluorescence was performed on frozen liver sections fixed with acetone/methanol 50:50 using the following primary antibodies: α-SMA (1:100, monoclonal Cy3-conjugated mouse . DAPI (4',6-diamidino-2-phenylindole) (Molecular Probes®, Invitrogen) was used to identify nuclei and ProLong® Gold antifade reagent (Molecular Probes®, Invitrogen) was used for mounting.
Confocal microscopy was performed using Leica TCS SP5 instrument (Leica Microsystems). The laser excitation lines used were 405, 488, 561 and 633 nm. The objective lens utilized was 63X with water as the immersion medium. The confocal images were acquired using sequential scanning and between lines mode to avoid cross-talk or bleed-through between fluorophores. Z-stacks obtained from optical slices of the 30 µm frozen section liver specimens were reconstructed and analyzed using Volocity® 3D Image Analysis Software 5.1 (Perkin Elmer).
Statistical analysis
Statistical analyses were performed using SPSS17.0 for Windows (Chicago, USA). Central tendency was expressed as median and range. Continuous variables were compared using MannWhitney-U test and categorical variables were compared using Chi-square or Fisher's exact test as appropriate. Spearman method was used for correlation analysis. A p-value <0.05 was considered significant.
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John Wiley & Sons, Inc. Table 1 shows the patients' gender, age and liver fibrosis stages in both cohorts. In the Sydney cohort there were 194 biopsies taken and HCV genotype (G) was documented as G1 38.1%, G2
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RESULTS
Patient populations and description of the ductular reaction
1%, G3 23.8%, G4 10.5%, G6 1%, and unknown 25.7%. The distribution of steatosis in this cohort was grade 0 in 54.1%, grade 1 in 27.8%, grade 2 in 9.3% and grade 3 in 8.8% of specimens. Three patients had cholestatic hepatitis C (Table 2 ) and these patients had a higher median viral load compared to non-cholestatic patients (8.7x10^7 IU/ml vs. 2.84x10^6, p<0.005). The DR in the liver with cholestatic hepatitis C seemed to be more extensive than in the liver with non-cholestatic hepatitis C (supplementary Table 4 ), however given the small number of specimens with cholestatic hepatitis C, these did not influence the overall final correlation results (supplementary Figure 7 and Table 5 ) and a subanalysis was unattainable. The DR appeared mainly in the periphery of portal tracts as irregular strings of proliferating biliary epithelium with seemingly isolated single cells in adjacent areas, which are labeled HPCs ( Figure 1A and B). The morphology of the DR was consistent with previously described results in the non-LT setting, independent of the antibody used for quantitation. 13, 33, 34 The extent of the DR and number of HPC correlated significantly ( Figure   1C , r 2 =0.299, p<0.001). 
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Assessment of both hepatocyte replicative arrest and proliferation showed that these did differ to both the DR and α-SMA expression with each stage of fibrosis ( Figure 3E and F). There was a clear early increase in both p21 and Ki-67 staining in HCV recurrence without fibrosis (F0), however there were no further significant changes through to advanced fibrosis. This was reflected in the ratio of p21/Ki-67 expression, which was significantly greater at F0 compared to control (p=0.012).
Although p21 and Ki-67 expression peaked in mild fibrosis and decreased in moderate-advanced fibrosis, the differences were not significant. Steatosis is known to be a co-factor in HCVassociated liver injury. 13, [36] [37] [38] [39] [40] [41] [42] However, the degree of liver steatosis in the post-LT setting did not correlate with the DR (Table 3) or fibrosis in liver with HCV recurrence post-LT (data not shown).
The HPC response was similar to the development of the DR and α-SMA expression accompanying progressive fibrosis ( Figure 3B ). Further, the DR correlated positively with the number of HPCs ( Figure 1C ). An extensive correlative analysis showed that not only did the DR significantly correlate with fibrosis ( (Table 3) .
Confirmation of findings in a separate cohort
The extent of the DR and numbers of HPC were evaluated in the Loma Linda cohort using Kpan as a marker of ductular epithelium and HPC. Representative photomicrographs of K7, Kpan and K19 staining in F0, F2 and F4 fibrosis in post-LT patients illustrate that the DR/HPC response increased in proportion to the degree of fibrosis, irrespective of the DR/HPC marker used ( Figure 4A ). This is consistent with published studies. 17, 32, 33 Confocal analysis of K7 and Kpan immunofluorescent staining confirmed that these two markers identified the same cell populations ( Figure 4B ).
Quantitation of Kpan-positive cells showed a strong significant correlation between the extent of the DR and numbers of HPC ( Figure 5A and B, p=0.0001) and confirmed that the DR directly correlates with the fibrosis severity in both pre-as well as post-LT HCV-infected livers ( Figure 5C and D). Further, in the Loma Linda cohort it was also demonstrated in both patient groups that the DR correlated to hepatic inflammation, as judged by quantitation of cells positive for the leukocyte common antigen CD45 and represented by Ishak's inflammation score ( Figure 5E and F).
Confocal immunofluorescence characterization of the ductular reaction
Confocal analysis of K7-positive DR structures and α-SMA-expressing HSCs in post-LT liver sections showed that the DR is mostly seen in periportal regions, which is also the location of most activated, fibrosis-driving HSCs in HCV-infected livers. Importantly, these cell populations were always in close proximity. However, despite their significant correlation, K7-and α-SMA-positive structures never co-localized within the same cell ( Figure 6A-C) . were undertaken contemporaneously and importantly yielded the same results, demonstrating that our findings were significant independent of the antibodies and methodologies used for analyses. In addition, we have shown replicative arrest precedes hepatocyte proliferation in early stage injury.
The DR was not evident in donor livers or in non-diseased livers and was only activated in response to liver injury, which is consistent with observations in pre-LT patients with HCV infection. 13, 15 In the Sydney cohort, we demonstrated in post-LT livers that the DR only correlated significantly with portal but not lobular necroinflammatory activity. The Loma Linda cohort confirmed and extended these findings by demonstrating a positive correlation between the DR, fibrosis and inflammation in both pre-and post-LT patients. Since HCV-induced hepatic fibrosis typically occurs in the periportal area, this further supports the hypothesis that portal inflammation is likely to be the common stimulus driving HPC expansion, the DR, HSC activation and consequently fibrogenesis.
The DR in the liver with cholestatic hepatitis C seemed to be more exaggerated than in the liver with non-cholestatic hepatitis C. However meaningful subanalysis was unattainable given the very small number of specimens with cholestatic hepatitis C, and further study is warranted on this special population.
It has been suggested that HPC activation can be triggered by impaired hepatocyte replication. 22, 45 Previous studies have reported a correlation between hepatocyte replicative arrest and HPC/DR proliferation in the non-LT setting with HCV-related liver injury 13, 34 , which is associated with p21-regulated hepatocyte G1 arrest. 46 In post-LT HCV-infected livers, increased hepatocyte replicative arrest and Ki-67-positivity were seen in liver without significant fibrosis (F0) and both remained significantly increased in early and advanced stage fibrosis. We can postulate that this reflects Liver Transplantation increased numbers of hepatocytes in G1-arrest in an initial attempt to compensate for hepatocytes loss, which then in turn leads to HPC/DR activation. Importantly, there was no significant difference in either p21 or Ki-67 expression between fibrosis stages suggesting that this is a sustained response to HCV-associated liver injury following LT. The reduction in both hepatocyte replicative arrest and proliferation markers in the advanced stages of liver fibrosis, though not statistically significant, might reflects an overall loss in the hepatocytes mass accompanying the development of cirrhosis.
Damage to hepatocytes may also contribute to the activation of HSCs. 47 In livers with HCV recurrence post-LT, there was a significant increase in activated HSCs compared to donor livers.
This finding was associated with the highest hepatocyte replicative arrest to proliferation ratio. Our results are consistent with previously published data, which demonstrated that HSC activation may start early in recurrent HCV disease post-LT, which can predict rapid disease progression. 31, 48, 49 As expected, the numbers of activated HSCs continued to increase in the post-LT biopsies with progressive fibrosis, confirming their pivotal role in recurrent HCV-associated liver injury.
Given its proximity to and positive correlations with fibrosis, the DR has been suggested to contain
HSCs and mesenchymal cell populations. 31, 43, 50, 51 Detailed analysis using high power confocal microscopy and 3D image analyses, however, showed that markers for DR cells and activated
HSCs never co-localized. These findings are consistent with the observations of Ruddell et al., which also demonstrated that HPCs and HSCs are closely associated but remain as distinct cells during the wound healing response. 23 Inflammation and fibrogenesis have previously been shown to be co-regulated within the liver. ethionine-supplemented diet. 17, 52 Moreover, inhibition of the HPC response to liver injury prevents liver fibrosis and cancer development in animal models 54 , whilst augmentation of the HPC response results in more severe liver fibrosis. 52 Our observation of the early detection of activated HSCs prior to the appearance of fibrosis supports the growing body of evidence that early activation precedes fibrosis and occurs contemporaneously with HPC activation. 48, 49 Due to the cross-sectional nature of our study, it remains unclear as to whether the early activation of HSCs might be predictive of earlier and progressive liver fibrosis with worse outcome.
Longitudinal studies in the same patients would be required to confirm this as a marker to identify individuals with HCV recurrence post-LT who may benefit from close monitoring and early antiviral therapy.
In summary, our data indicate that post-LT recurrent HCV-induced liver injury contributes to hepatocellular damage and impaired regeneration with subsequent HPC proliferation, DR formation and HSC activation. The exact mechanisms and sequences of these injury responses are unclear.
However, the current and previous studies indicate that hepatic inflammation occurring in HCVassociated liver injury, either pre-or post-LT, would appear to drive both fibrosis and HPC proliferation and the DR. Our study has confirmed and extended previous observations in a variety of pre-LT chronic liver diseases linking inflammation, HPC proliferation, the DR and fibrogenesis.
We have now shown a similar response with post-LT recurrent HCV injury. It is likely that future therapies for chronic liver disease, which target the mechanisms underlying the inflammation-HPC/DR-fibrogenesis association, are likely to be applicable in both pre-and post-LT HCVassociated liver disease. Table 1 . Table 1 . 119x130mm (300 x 300 DPI) 
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Figure 5 Quantitation of the DR using pan-keratin in the Loma Linda cohort The DR, as assessed by pan-keratin (Kpan) staining quantitation, shows significant correlations with HPC numbers (A, B), fibrosis grade (C, D) and hepatic inflammation according to Ishak score (E, F) in both pre-LT as well as post-LT setting. Data are represented as means +/-SE (*p<0.05, **p<0.01). 109x130mm (300 x 300 DPI) Figure 6 . Confocal microscopy of the DR and activated HSCs. Confocal analysis of immunofluorescent stainings for keratin-7 (K7, DR and HPCs, green), α-SMA (activated HSCs, red) and DAPI (nuclear-stain, blue) demonstrates that the DR (B) and activated myofibroblasts (C) are identified in very close proximity in periportal areas. However, despite their strong correlation these markers did not co-localize and definitely distinguish distinct cell populations (A, merged). 189x108mm (300 x 300 DPI)
